Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Esomeprazole 40 mg vs Nexium 40 mg in Healthy Thai Volunteers
NCT06233097Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of esomeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Bio-innova. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration, Maximal measured plasma concentration and 1 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06233097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233097.